Search

Your search keyword '"Fox ML"' showing total 3 results
Start Over Author "Fox ML" Journal american journal of hematology
3 results on '"Fox ML"'

1. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.

Author

Hernández-Sánchez A, Villaverde-Ramiro Á, Arellano-Rodrigo E, Garrote M, Martín I, Mosquera-Orgueira A, Gómez-Casares MT, Ferrer-Marín F, Such E, Velez P, Ayala R, Angona A, de Las Heras N, Magro E, Mata-Vázquez MI, Fox ML, de Villambrosía SG, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín A, Raya JM, González JA, Cuevas B, Xicoy B, Pérez-Encinas M, Bellosillo B, Álvarez-Larrán A, Hernández-Rivas JM, and Hernández-Boluda JC

Subjects
Humans, Prognosis, Mutation, Janus Kinase 2 genetics, Gene Frequency, Primary Myelofibrosis diagnosis, Primary Myelofibrosis genetics
Abstract

Prognostic impact of non-MPN driver gene mutations in primary myelofibrosis. MIPSS70: Mutation-Enhanced International Prognostic Score System., (© 2024 Wiley Periodicals LLC.)

Published
2024
Full Text
View/download PDF

2. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19.

Author

Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Carli G, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nałęcz AK, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Rambaldi A, and Vannucchi AM

Subjects
Humans, Triage, Hospitalization, COVID-19, Myeloproliferative Disorders complications, Myeloproliferative Disorders therapy, Bone Marrow Neoplasms
Published
2022
Full Text
View/download PDF

3. Second cancers in MPN: Survival analysis from an international study.

Author

Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Pane F, De Stefano V, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, and Barbui T

Subjects
Age Factors, Aged, Case-Control Studies, Disease-Free Survival, Female, Follow-Up Studies, Humans, Male, Middle Aged, Survival Rate, Hematologic Neoplasms mortality, Myeloproliferative Disorders mortality, Neoplasms, Second Primary mortality
Abstract

One out of ten patients with Philadelphia-negative myeloproliferative neoplasms (MPN) develop a second cancer (SC): in such patients we aimed at assessing the survival impact of SC itself and of MPN-specific therapies. Data were therefore extracted from an international nested case-control study, recruiting 798 patients with SC diagnosed concurrently or after the MPN. Overall, 2995 person-years (PYs) were accumulated and mortality rate (MR) since SC diagnosis was 5.9 (5.1-6.9) deaths for every 100 PYs. A "poor prognosis" SC (stomach, esophagus, liver, pancreas, lung, ovary, head-and-neck or nervous system, osteosarcomas, multiple myeloma, aggressive lymphoma, acute leukemia) was reported in 26.3% of the patients and was the cause of death in 65% of them (MR 11.0/100 PYs). In contrast, patients with a "non-poor prognosis" SC (NPPSC) incurred a MR of 4.6/100 PYs: 31% of the deaths were attributed to SC and 15% to MPN evolution. At multivariable analysis, death after SC diagnosis was independently predicted (HR and 95% CI) by patient age greater than 70 years (2.68; 1.88-3.81), the SC prognostic group (2.57; 1.86-3.55), SC relapse (1.53; 10.6-2.21), MPN evolution (2.72; 1.84-4.02), anemia at SC diagnosis (2.32; 1.49-3.59), exposure to hydroxyurea (1.89; 1.26-2.85) and to ruxolitinib (3.63; 1.97-6.71). Aspirin was protective for patients with a NPPSC (0.60; 0.38-0.95). In conclusion, SC is a relevant cause of death competing with MPN evolution. Prospective data are awaited to confirm the role of cytoreductive and anti-platelet drugs in modulating patient survival after the occurrence of a SC., (© 2019 Wiley Periodicals, Inc.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results